Figure 3.

Expression of IDO1 is up-regulated by estrogen in the ectopic lesion. (a) Complete gating strategy of ectopic ESCs. Gate R2 is inclusive of gate R1; cells of gate R2 represent ESCs. (b) Complete gating strategy of monocytes. Gate R2 is inclusive of gate R1; cells of gate R2 represent CD14⁺ cells. (c) Flow cytometric analysis was used to determine the expression of IDO1 in ESCs (Ctrl), estrogen-treated ESCs (E₂), monocyte-treated ESCs (M), and monocyte-treated ESCs in the presence of estrogen (M+E₂). (d) MFI of the expression of IDO1 in groups shown in (c). Values indicate mean±S.D., n=5, *P<0.05, two-tailed, paired t-test. (e) Flow cytometric analysis was used to determine the expression of IDO1 in monocytes (Ctrl), estrogen-treated monocytes (E₂), ESCs-treated monocytes (e), and ESCs-treated monocytes in the presence of estrogen (E+E₂). (f) MFI of the expression of IDO1 in groups shown in (e). Values indicate mean±S.D., n=13, *P<0.05, two-tailed, paired t-test. (g) ESCs were pretreated with estrogen receptor-α inhibitor (ER_αi), estrogen receptor-β inhibitor (ER_βi), or estrogen receptors inhibitor (ER_i) for 24 h, washed and then estrogen was added to each group, except control group. Control (Ctrl) group contained untreated ESCs. Flow cytometric analysis was used to determine the expression of IDO1 in ESCs from these groups. (h) MFI of the expression of IDO1 shown in (g). Values indicate mean±S.D., n=4, *P<0.05, **P<0.01, two-tailed, paired t-test